Salvage radiotherapy for postoperative locoregional failure in esophageal cancer: a systematic review and meta-analysis
- PMID: 33912933
- DOI: 10.1093/dote/doab020
Salvage radiotherapy for postoperative locoregional failure in esophageal cancer: a systematic review and meta-analysis
Abstract
Locoregional recurrences following surgery for esophageal cancers represent a significant clinical problem with no standard recommendations for management. We conducted this systematic review and meta-analysis with the objective of studying safety and efficacy of salvage radiotherapy in this setting. All prospective and retrospective cohort studies, which studied patients who developed locoregional recurrence following initial radical surgery for esophageal cancer and subsequently received salvage radiation therapy (RT)/chemoradiation with all relevant information regarding survival outcome and toxicity available, were included. The quality of eligible individual studies was assessed using the Newcastle-Ottawa Scale score for risk of bias. R package MetaSurv was used to obtain a summary survival curve from survival probabilities and numbers of at-risk patients collected at various time points and to test the overall heterogeneity using the I2 statistic. Thirty studies (27 retrospective, 3 prospective) published from 1995 to 2020 with 1553 patients were included. The median interval between surgery and disease recurrence was 12.5 months. The median radiation dose used was 60 Gy and 57% received concurrent chemotherapy. The overall incidence of acute grade 3/4 mucositis and dermatitis were 8 and 4%, respectively; grade 3/4 acute pneumonitis was reported in 5%. The overall median follow-up of all studies included was 27 months. The 1-, 2- and 3-year overall survival (OS) probabilities were 67.9, 35.9 and 30.6%, respectively. Factors which predicted better survival on multivariate analysis were good PS, lower group stage, node negativity at index surgery, longer disease-free interval, nodal recurrence (as compared to anastomotic site recurrence), smaller disease volume, single site of recurrence, RT dose >50 Gy, conformal RT, use of concomitant chemotherapy and good radiological response after radiotherapy. Salvage radiotherapy with or without concomitant chemotherapy for locoregional recurrences after surgery for esophageal cancer is safe and effective. Modern radiotherapy techniques may improve outcomes and reduce treatment-related morbidity.
Keywords: carcinoma esophagus; radiation therapy; recurrence; salvage.
© The Author(s) 2021. Published by Oxford University Press on behalf of International Society for Diseases of the Esophagus. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Similar articles
-
High dose radiation with chemotherapy followed by salvage esophagectomy among patients with locally advanced esophageal squamous cell carcinoma.Thorac Cancer. 2017 May;8(3):219-228. doi: 10.1111/1759-7714.12427. Epub 2017 Mar 21. Thorac Cancer. 2017. PMID: 28322515 Free PMC article.
-
Definitive chemoradiation for locoregional recurrences of esophageal cancer after primary curative treatment.Dis Esophagus. 2017 Feb 1;30(2):1-5. doi: 10.1111/dote.12539. Dis Esophagus. 2017. PMID: 27766725
-
Salvage radiotherapy for locoregional recurrence of esophageal cancer after surgery.Jpn J Clin Oncol. 2025 Jan 8;55(1):59-66. doi: 10.1093/jjco/hyae124. Jpn J Clin Oncol. 2025. PMID: 39239699
-
Salvage reirradiation for locoregional failure after radiation therapy for prostate cancer: who, when, where and how?Cancer Radiother. 2014 Oct;18(5-6):524-34. doi: 10.1016/j.canrad.2014.07.153. Epub 2014 Sep 2. Cancer Radiother. 2014. PMID: 25192626 Review.
-
How successful is high-dose (> or = 60 Gy) reirradiation using mainly external beams in salvaging local failures of nasopharyngeal carcinoma?Int J Radiat Oncol Biol Phys. 1998 Mar 1;40(4):897-913. doi: 10.1016/s0360-3016(97)00854-7. Int J Radiat Oncol Biol Phys. 1998. PMID: 9531376 Review.
Cited by
-
Salvage Radiotherapy for Loco-regional Recurrence of Esophageal Cancer Following Surgery.Cancer Res Treat. 2025 Jan;57(1):165-173. doi: 10.4143/crt.2024.191. Epub 2024 Jul 26. Cancer Res Treat. 2025. PMID: 39054622 Free PMC article.
-
Radiotherapy and chemoradiotherapy for postoperative recurrence in patients with esophageal squamous cell carcinoma.Cancer Med. 2024 Aug;13(16):e70108. doi: 10.1002/cam4.70108. Cancer Med. 2024. PMID: 39161098 Free PMC article.
-
Clinical Analysis of Severe Radiation Pneumonia.Int J Gen Med. 2021 Jun 16;14:2581-2588. doi: 10.2147/IJGM.S311569. eCollection 2021. Int J Gen Med. 2021. PMID: 34163227 Free PMC article.
-
Salvage Chemoradiotherapy for Loco-Regional Recurrence of Esophageal Squamous Cell Carcinoma After Esophagectomy.J Clin Med. 2025 Feb 25;14(5):1540. doi: 10.3390/jcm14051540. J Clin Med. 2025. PMID: 40095468 Free PMC article.
-
Sintilimab as maintenance treatment for local/regional recurrent esophageal squamous carcinoma after concurrent chemoradiotherapy: a single-arm Ib/II phase study.Front Immunol. 2023 May 31;14:1193394. doi: 10.3389/fimmu.2023.1193394. eCollection 2023. Front Immunol. 2023. PMID: 37325650 Free PMC article. Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical